Table 1.
Characteristics of Patient Population and Pre-HCT Exposure
| Characteristic | Cases* (n = 60)
|
Controls* (n = 166)
|
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age at initial diagnosis, years | |||||
| Mean | 43.0 | 43.8 | |||
| SD | 13.7 | 13.3 | .70 | ||
| Female sex | 30 | 50.0 | 73 | 44.0 | .42 |
| Ethnicity/race | |||||
| Non-Hispanic white | 37 | 61.7 | 112 | 67.5 | |
| Others | 23 | 38.3 | 54 | 32.5 | .52 |
| Diagnosis† | |||||
| Lymphoma | 32 | 53.3 | 73 | 44.0 | |
| Non-Hodgkin's lymphoma | 25 | 41.7 | 50 | 30.1 | |
| Hodgkin's lymphoma | 7 | 11.7 | 23 | 13.9 | |
| Nonlymphoma | 28 | 46.7 | 93 | 56.0 | .21 |
| Multiple myeloma | 9 | 15.0 | 25 | 15.1 | |
| Acute lymphatic leukemia | 9 | 15.0 | 8 | 4.8 | |
| Acute myeloid leukemia | 8 | 13.3 | 31 | 18.7 | |
| Chronic myeloid leukemia | 2 | 3.3 | 18 | 10.8 | |
| Other | 0 | 0 | 11 | 6.6 | |
| Pre-HCT comorbidity | |||||
| Hypertension | 5 | 8.3 | 14 | 8.4 | 1.00 |
| Renal insufficiency | 4 | 6.7 | 4 | 2.4 | .26 |
| Chronic lung disease | 6 | 10.0 | 7 | 4.2 | .10 |
| Thyroid, hyper/hypo | 5 | 8.3 | 11 | 6.6 | .66 |
| Diabetes | 2 | 3.3 | 4 | 2.4 | .70 |
| Dyslipidemia | 1 | 1.7 | 6 | 3.6 | .40 |
| ≥ 2 comorbidities | 5 | 8.3 | 11 | 6.6 | .77 |
| Pre-HCT courses of chemotherapy | |||||
| Mean | 8.6 | 4.9 | |||
| SD | 4.9 | 4.1 | < .01 | ||
| Anthracycline, mg/m2 | |||||
| Pre-HCT | < .01 | ||||
| Mean | 261.4 | 171.8 | |||
| SD | 134.4 | 125.8 | |||
| Lifetime anthracycline | < .01 | ||||
| Mean | 285.3 | 175.6 | |||
| SD | 144.0 | 128.2 | |||
| Cyclophosphamide, g/m2 | |||||
| Mean | 2.3 | 1.6 | .10 | ||
| SD | 3.0 | 2.4 | |||
| Cisplatin, mg/m2 | |||||
| Mean | 58.3 | 43.7 | .35 | ||
| SD | 104.6 | 101.7 | |||
| Melphalan, mg/m2 | |||||
| Mean | 10.1 | 3.9 | .30 | ||
| SD | 42.3 | 22.9 | |||
| Mediastinal radiation | 6 | 10.0 | 14 | 8.4 | .71 |
Abbreviations: HCT, hematopoietic cell transplantation; SD, standard deviation.
*
Group matching criteria included age at HCT (± 5 years), type of HCT (autologous v allogeneic), year of HCT (± 2 years), and duration of follow-up.
†
Analyzed as lymphoma (non-Hodgkin's lymphoma, Hodgkin's lymphoma) versus nonlymphoma (multiple myeloma, acute lymphatic leukemia, acute myeloid leukemia, chronic myeloid leukemia, and other).